Testing a new four-drug combination for hard-to-treat blood cancer

Plain-English translation of NCT05896228 on ClinicalTrials.gov ↗ · Source last updated March 2026 · Translation generated June 2026 · How we translate trials

Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.

What is this trial?

This study is testing a new four-drug combination called Iber-KDd to treat multiple myeloma that has returned or stopped responding to previous treatments. The combination includes , , , and — medications that work in different ways to fight cancer cells. Researchers want to see if this treatment combination can shrink the cancer or prevent it from coming back better than standard treatments currently available.

Multiple myeloma is a serious blood cancer, and when it comes back or stops responding to initial treatments, patients have limited options. This trial exists to find out if combining these four medications in a new way might offer better results and help patients live longer with better quality of life.

Do you qualify?

You likely qualify if…

you have been diagnosed with multiple myeloma that has come back or is no longer responding to treatment
you have received 1 to 3 previous treatment regimens for your myeloma, and at least one included a drug called lenalidomide
your cancer can be measured by blood or urine tests showing active disease
you are between 18 and 75 years old
you have adequate kidney, liver, and blood cell function based on recent lab tests
you are able and willing to take a blood thinner medication to prevent clots during treatment

You likely don't qualify if…

you previously received daratumumab (a CD38-targeted therapy) and either progressed while taking it, progressed within 60 days of stopping it, or had to stop it due to side effects
you previously received carfilzomib and either progressed while taking it, progressed within 60 days of stopping it, or had to stop it due to side effects
you are pregnant or breastfeeding, or unwilling to use reliable contraception during and after the study
you have severe kidney disease with a creatinine clearance below 60 ml/min
you have very low blood cell counts or liver function that is significantly abnormal

What participation looks like

You would receive the four-drug combination therapy in 28-day cycles for up to 8 months (about 8 cycles of treatment). Before each treatment cycle, you'll receive medications to help prevent side effects. If your cancer responds well and doesn't get worse, you'll continue with a single medication ( alone) for up to 12 additional months. Throughout the study, you'll have regular visits for blood tests, scans, and check-ins to monitor how you're doing and track whether the cancer is shrinking. Even if your cancer progresses and you stop the study treatment, researchers will continue to follow your health for up to 3 years.

AI-generated summary from trial data · Jun 10, 2026 · Not medical advice

Trial locations(1 site)

United States

University of Miami, Miami, Florida